论文部分内容阅读
目的:探讨苯那普利联合霉酚酸酯(MMF)治疗早期糖尿病肾病(DN)的临床疗效。方法:30例早期Ⅱ型糖尿病肾病(DN)患者,随机分为治疗组和对照组,治疗组使用苯那普利、霉酚酸酯(MMF)联用,对照组单用苯那普利,疗程12周。观察两组患者治疗前后的平均动脉压(MAP)、尿白蛋白排泄率(UAER)、内生肌酐清除率(Ccr)、血清肌酐(SCr)、空腹血糖(FBG)、糖化血红蛋白(HbA1C)、血脂等变化。结果:治疗组与观察组对早期DN均有明显降低血压、UAER、SCr的作用,各组在治疗前后差异具有明显统计学意义(P<0.01或P<0.05),但治疗组效果更好,尤其降低UAER作用有明显差异(P<0.01),各组间FBG、CH、TG治疗前及治疗后比较无统计学意义。结论:苯那普利联合MMF治疗早期DN有确切疗效。
Objective: To investigate the clinical efficacy of benazepril combined with mycophenolate mofetil (MMF) in the treatment of early diabetic nephropathy (DN). Methods: Thirty patients with early type 2 diabetic nephropathy (DN) were randomly divided into treatment group and control group. The treatment group was benazepril combined with mycophenolate mofetil (MMF). The control group was benazepril alone, Treatment for 12 weeks. The mean arterial pressure (MAP), urinary albumin excretion (UAER), creatinine clearance (Ccr), serum creatinine (SCr), fasting blood glucose (FBG), HbA1C, Blood lipids and other changes. Results: Both the treatment group and the observation group had significantly lower blood pressure, UAER and SCr on the early stage of DN. There was significant difference between before and after treatment in each group (P <0.01 or P <0.05), but the effect of the treatment group was better, Especially, the effect of reducing UAER was significantly different (P <0.01). There was no significant difference between FBG, CH and TG before treatment and after treatment. Conclusion: Benazepril combined with MMF has the exact effect on early DN.